Marc Wortman
The blood-brain barrier gets no respect. It should. Fewer than 2% of drugs have the requisite properties to get across the BBB. That’s still better than biopharmaceuticals’ success rate. Without assistance, no large molecule drug can penetrate the brain at all—keeping many of the most promising central nervous system therapeutics from ever reaching their targets
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?